{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:42:47Z","timestamp":1762299767523,"version":"build-2065373602"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["enviromicro-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Microbial Biotechnology"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Under the pressure of the COVID\u201019 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus\u2010vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts.<\/jats:p>","DOI":"10.1111\/1751-7915.13818","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T17:59:00Z","timestamp":1620496740000},"page":"1246-1257","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["COVID\u201019: vaccine\u2019s progress"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-8583","authenticated-orcid":false,"given":"Harald","family":"Br\u00fcssow","sequence":"first","affiliation":[{"name":"Department of Biosystems Laboratory of Gene Technology KU Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028436"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe1502"},{"key":"e_1_2_2_5_1","doi-asserted-by":"crossref","DOI":"10.1101\/2021.03.01.21252652","volume-title":"Early effectiveness of COVID\u201019 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England","author":"Bernal J. L.","year":"2021"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.13800"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03326-w"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00268-9"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf6840"},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.370.6521.1151"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03563-z"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765"},{"volume-title":"Europe needs quicker vaccinations and more stimulus","author":"The Economist Europe\u2019s vaccine roll\u2010out","key":"e_1_2_2_14_1"},{"key":"e_1_2_2_15_1","article-title":"Safety and immunogenicity of an inactivated SARS\u2010CoV\u20102 vaccine, BBV152: interim results from a double\u2010blind, randomised, multicentre, phase 2 trial, and 3\u2010month follow\u2010up of a double\u2010blind, randomised phase 1 trial","author":"Ella R.","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_2_16_1","article-title":"Safety and immunogenicity of an inactivated SARS\u2010CoV\u20102 vaccine, BBV152: a double\u2010blind, randomised, phase 1 trial","author":"Ella R.","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18077-5"},{"volume-title":"Sanofi and GSK announce a delay in their adjuvanted recombinant protein\u2010based COVID\u201019 vaccine programme to improve immune response in the elderly","year":"2020","author":"GSK Press Release","key":"e_1_2_2_18_1"},{"key":"e_1_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100230"},{"key":"e_1_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.026"},{"key":"e_1_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826"},{"key":"e_1_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00020-7"},{"key":"e_1_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026920"},{"key":"e_1_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03504-w"},{"key":"e_1_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026785118"},{"key":"e_1_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31866-3"},{"key":"e_1_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"e_1_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026153118"},{"key":"e_1_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102214"},{"key":"e_1_2_2_30_1","article-title":"China COVID vaccine reports mixed results \u2010 what does that mean for the pandemic?","author":"Mallapaty S.","year":"2021","journal-title":"Nature"},{"key":"e_1_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"e_1_2_2_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_2_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1"},{"key":"e_1_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00241-5"},{"key":"e_1_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2034717"},{"key":"e_1_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201"},{"key":"e_1_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3035-9"},{"key":"e_1_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21665-8"},{"key":"e_1_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8"},{"volume-title":"Effectiveness of First Dose of COVID\u201019 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People","year":"2021","author":"Vasileiou E.","key":"e_1_2_2_40_1"},{"key":"e_1_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_2_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3"},{"key":"e_1_2_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.043"},{"key":"e_1_2_2_44_1","doi-asserted-by":"crossref","DOI":"10.1101\/2020.08.17.20176651","volume-title":"RNA\u2010Based COVID\u201019 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study","author":"Walsh E.E.","year":"2020"},{"key":"e_1_2_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"e_1_2_2_46_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.68808"},{"key":"e_1_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2032195"},{"key":"e_1_2_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7"},{"key":"e_1_2_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30831-8"},{"key":"e_1_2_2_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21639-w"},{"key":"e_1_2_2_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2599-8"},{"key":"e_1_2_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4"}],"container-title":["Microbial Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-7915.13818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1751-7915.13818","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sfamjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-7915.13818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:50:08Z","timestamp":1762257008000},"score":1,"resource":{"primary":{"URL":"https:\/\/sfamjournals.onlinelibrary.wiley.com\/doi\/10.1111\/1751-7915.13818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/1751-7915.13818"],"URL":"https:\/\/doi.org\/10.1111\/1751-7915.13818","archive":["Portico"],"relation":{},"ISSN":["1751-7915","1751-7915"],"issn-type":[{"type":"print","value":"1751-7915"},{"type":"electronic","value":"1751-7915"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"2021-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}